Welcure Drugs & Pharmaceuticals Announces 1:10 Bonus and Stock Split: Today Is the Last Day to Buy Shares Before October 16 Ex-Date

October 15, 2025: Today marks the final opportunity for investors to purchase shares of Welcure Drugs and Pharmaceuticals Ltd to be eligible for the company’s 1:10 bonus issue and stock split. The record and ex-date for these actions is October 16, 2025, after which the shares will trade on an adjusted basis

Welcure Drugs & Pharmaceuticals Ltd is a publicly traded pharmaceutical company involved in creating and selling formulations spanning across different therapeutic categories. The company’s current market cap is ₹94.90 crore.

Details of the Corporate Actions

According to the proposal, shareholders registered as of 16 October will receive one bonus ordinary share for every ten shares held. The bonus shares will be simultaneously split into ten smaller shares, reducing the face value from ₹10 to ₹1 for each ordinary share. The twin action is designed to increase stock liquidity, ease affordability for retail investors and broaden the shareholder base of the company.

Eligibility Criteria For Investors

To be eligible for the bonus and the split, investors must complete their share purchase by the close of trading on October 15. Any shares purchased on or after October 16 will not be entitled to the bonus or the split, as shares will be traded ex-bonus and ex-split from that date.

Recent Stock Performance

As of 11:30 AM IST, shares of Welcure Drugs & Pharmaceuticals were trading at ₹8.14, representing a decrease of 3.55% from the previous closing price of ₹8.45. Throughout the evaluated period, the stock has delivered strong returns: 27% over 1 week, 54% over 2 weeks, and more than 314% over 5 years, demonstrating investor confidence in the company.

Outlook

Welcure Drugs & Pharmaceuticals Ltd presents an interesting opportunity within the small-cap pharmaceutical space. The company has shown consistent growth in both price and performance, backed by strong fundamentals and expanding market presence.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations